Full-Time

Senior Supplier Quality Engineer

Posted on 5/9/2026

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$110k - $120k/yr

+ Bonus

Houston, TX, USA

In Person

Category
QA & Testing (1)
Required Skills
Risk Management
Requirements
  • A Bachelor's Degree in Engineering is required
  • 8+ Years of Quality or Manufacturing Engineering
  • Understanding of basic quality engineering principles including, but not limited to: quality leadership, implementation, acceptance sampling, statistical process control, lean business systems and other continuous improvement techniques, and risk management
  • Pragmatic and result-oriented: capable to prioritize and plan activities with specific attention to understand expectations of internal personnel and external stakeholders
  • Good team player: open and honest when communicating among peers and management. Resolves most issues with peers, but understands what issues are important to escalate to management
  • Project management skills including the ability to drive cross-functional internal and external teams to completion of projects within planned timeframes. Strong interpersonal skills
  • Sustained record of performance during tenure in previous position as shown through consistency with which metrics in their areas of responsibility meet performance objectives as established in Management Review and a track record of implementing improvements
Responsibilities
  • Leads the supplier selection, evaluation and approval process by assessing manufacturing/ technology capabilities, supplier risk levels, Quality Management System compliance, etc.
  • Serves as a core team member on component development teams by providing technical leadership and direction. Responsible for supplier process qualification, verification and validation activities
  • Reviews supplier process changes for completeness, accuracy, and safety/effectiveness including the identification of all impacts and timely management of these changes with to ensure continued supply of parts
  • Acts as business process owner for all supplier related nonconformance report (NCR) management system, including material review board (MRB) activities, monitoring the timeliness and effectiveness of the system and activities
  • Carries out supplier Quality Management System (QMS) and process audits
  • Collaborates with suppliers on process manufacturing process improvement, process validation (TMV, IQ, OQ and PQ) and value enhancement opportunities
  • Ensures ongoing compliance per ISO 13485 and MDSAP requirements
  • Collaborates with Purchasing and procurement functions to support business strategy initiatives including cost saving efforts, alternate sourcing, outsourced processes etc.
  • Provides quality criteria (risk assessment, acceptance criteria, sample size, parameter definition) for receiving inspection activities
  • Ensures that procedures and processes are maintained and updated to be consistent with regulatory changes including the development of more efficient QMS processes and global QMS processes
  • Compiles and presents quality data to management as requested and in management review
  • Contributes to successful regulatory audits by coordinating back room / front room activities or serving as a subject matter expert
  • Supports enterprise resource planning controls and develop systems to ensure that parts and services are provided by approved sources
  • Performs other duties as may be required by management
  • Location: Clear Lake, TX and travel up to 25%
Desired Qualifications
  • Experience working in a regulated environment industry such as a FDA medical device manufacturer preferred

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Next-generation aura6000 with MRI compatibility and 15-year battery launches 2026.
  • Medicare coverage application for VNS treatment-resistant depression supported by five peer-reviewed studies.
  • Debt reduction to $377M enables M&A and R&D investment for innovation.

What critics are saying

  • Third-party component supply constraints limit Essenz production despite capacity expansion plans.
  • $400 million litigation payment Q3 2026 reduces cash reserves by approximately 50%.
  • Cardiopulmonary 18.3% Q1 2026 growth unsustainable; normalization triggers analyst downgrades.

What makes LivaNova unique

  • Essenz heart-lung machine revenue exceeded 20% growth in Q3 2025 with China expansion.
  • aura6000 OSA device FDA approval positions LivaNova in underserved $2B+ market segment.
  • VNS therapy epilepsy reimbursement increased 48% January 2026, expanding addressable patient population.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at LivaNova who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Mar 19th, 2026
LivaNova's aura6000 system gains FDA approval for moderate to severe obstructive sleep apnea treatment

LivaNova has received FDA premarket approval for its aura6000 System to treat adults with moderate to severe obstructive sleep apnea. The device uses proximal hypoglossal nerve stimulation for patients with an apnea-hypopnea index between 15 and 65 who cannot tolerate or have failed first-line therapies like positive airway pressure. The approval follows the OSPREY randomised controlled trial, which met its primary endpoints after six months. At 12 months, 65% of treatment patients achieved responder status, defined as at least 50% improvement from baseline and an AHI below 20. LivaNova is preparing a next-generation device for FDA submission featuring MRI compatibility, remote configuration and rechargeable battery technology lasting up to 15 years. The company plans to commercialise the advanced system next year.

Yahoo Finance
Feb 25th, 2026
LivaNova reports Q4 2025 results with fifth consecutive year of double-digit EPS growth

LivaNova, a medical device company, held its fourth-quarter and full-year 2025 earnings call, reporting strong financial performance. The company delivered double-digit revenue growth, expanded adjusted operating margins and generated robust cash flow across its cardiopulmonary and epilepsy businesses. CEO Vladimir Makatsaria highlighted that 2025 marked the company's fifth consecutive year of double-digit earnings per share growth and third straight year of double-digit organic revenue growth. The company also made progress towards financial targets outlined at its November investor day. The earnings call included executives Vladimir Makatsaria, Chief Financial Officer Alex Shvartsburg, Chief Innovation Officer Ahmet Tezel and Vice President of Investor Relations Briana Gotlin. The company posted a complementary presentation summarising key points on its investor relations website.

Yahoo Finance
Feb 25th, 2026
LivaNova posts third consecutive year of double-digit growth, targets 80% Essence heart-lung machine placements by 2026

LivaNova, a medical technology company, reported its third consecutive year of double-digit organic revenue growth in 2025, driven by its Essence heart-lung machine and cardiopulmonary consumables. The company has issued 2026 revenue guidance of 6% to 7% growth. LivaNova is transitioning focus towards high-margin markets including obstructive sleep apnea, with clinical trial device approval expected in the first half of 2026. The epilepsy business received a boost from a 48% Medicare reimbursement increase effective January 2026. The company strengthened its balance sheet by reducing debt from $628 million to $377 million. LivaNova expects to maintain adjusted operating margins above 20% whilst increasing R&D investment. A $400 million litigation payment is anticipated in the third quarter of 2026.

PR Newswire
Feb 20th, 2026
Orrum partners with LivaNova to integrate CŌRE Insights analytics with Essenz Perfusion System

Orrum Clinical Analytics has announced a strategic partnership with LivaNova USA to integrate its CŌRE Insights analytics platform with LivaNova's Essenz Perfusion System. The collaboration will enable automatic transfer of perfusion case data from Essenz to Orrum's platform for post-operative analysis and peer benchmarking. The integration, called CoreInsights for Essenz, allows perfusion teams to access continuous data capture, clinically relevant analytics measuring adherence to hospital and national benchmarks, and actionable insights on practice patterns and performance indicators. Built within a Patient Safety Organization recognised by the US Department of Health and Human Services, the platform provides secure data visualisation and analytics across the patient care continuum. The partnership aims to support evidence-based performance improvement in cardiopulmonary bypass patient management and extracorporeal care.

BioSpace
May 1st, 2024
Livanova Reports First-Quarter 2024 Results

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.Financial Summary and Highlights(1). First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis. First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73